Cardio Diagnostics Holdings, Inc. announced that its PrecisionCHD and Epi+Gen CHD tests have received final pricing determinations from the Centers for Medicare & Medicaid Services (CMS). This decision follows the preliminary pricing determination made by CMS in August 2024.
The final 'gapfill' pricing determination is effective for claims with dates of service on or after January 1, 2025. This allows Medicare contractors to determine pricing for the tests based on actual cost data provided by Cardio Diagnostics.
This milestone is crucial for improving the risk assessment, diagnosis, management, and monitoring of coronary heart disease for Medicare patients. It brings the company closer to addressing significant unmet needs in cardiovascular care for this at-risk population.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.